Advocacy intelligence hub — real-time data for patient organizations
City of Hope Medical Center — PHASE3
Rutgers, The State University of New Jersey — PHASE2
All India Institute of Medical Sciences, Bhubaneswar — PHASE4
IRCCS Azienda Ospedaliero-Universitaria di Bologna
H. Lee Moffitt Cancer Center and Research Institute — PHASE1
AC.TA. S.r.l. — NA
Patrick Wagner, MD, FACS — PHASE2
First Affiliated Hospital of Wenzhou Medical University — PHASE2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences — PHASE3
UroGen Pharma Ltd. — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
RETEVMO
Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company
CAPRELSA(r)
Genzyme Corporation
CAPRELSA(r)
(vandetanib)Orphan drugstandardGenzyme Corporation
Kinase Inhibitor [EPC]
12.1 Mechanism of Action In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, T...
RETEVMO
(selpercatinib)Orphan drugstandardLoxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Selpercatinib is a kinase inhibitor. Selpercatinib inhibited wild-type RET and multiple mutated RET isoforms as well as VEGFR...
Mark Zafereo, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Matthew Krebs, Dr
The Christie Hospital
Elizabeth G Grubbs, CNA
M.D. Anderson Cancer Center
📍 MORRISON, TN
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
Annamaria Colao
"Federico II" University of Naples, Italy
Giuseppe Procopio, MD, R. Ph
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
📍 RAHWAY, NJ